Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
Novo Nordisk(NVO) stock is priced at $47.05, giving the company a market capitalization of 209.19B. It carries a P/E multiple of 13.92 and pays a dividend yield of 2.6%.
As of 2025-12-08, Novo Nordisk(NVO) stock has fluctuated between $46.35 and $48.32. The current price stands at $47.05, placing the stock +1.5% above today's low and -2.6% off the high.
Novo Nordisk(NVO) shares are trading with a volume of 9.29M, against a daily average of 22.52M.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $112.52 and a 52-week low of $43.08.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $112.52 and a 52-week low of $43.08.
NVO News
Argus downgraded Novo Nordisk (NVO) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...
Argus downgraded Novo Nordisk (NVO) to Hold from Buy. The company has seen the market share of its GLP-1 drugs – Wegovy and Ozempic – decline in recent quarters...
If you have been wondering whether Novo Nordisk is starting to look like a bargain after its big run in recent years, you are not alone. This breakdown is desig...
Analyst ratings
56%
of 32 ratingsMore NVO News
Key Points Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's p...
Prices are going down for Novo Nordisk's weight-loss drug Wegovy. How much does Novo Nordisk’s weight-loss drug Wegovy actually cost? It depends on a patient’...
Hims announces acquisition of Canadian telehealth firm Livewell Hims & Hers rose in early trading after it announced its acquisition of Livewell, a Canadian te...
There is more to this news than meets the eye. The past two years have been challenging for Novo Nordisk (NVO +0.16%). The Denmark-based pharmaceutical company...
